Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexmedetomidine + esketamine + lidocaine
- Development stage
- Unknown
- Lead developer
- Peking University First Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The combination of dexmedetomidine, esketamine, and lidocaine is an intravenous anesthetic and analgesic regimen being investigated for its opioid-sparing effects in patients with obesity undergoing bariatric surgery. Developed and studied by Yan'an Hospital of Kunming City, this multimodal approach leverages the distinct mechanisms of its three components to optimize perioperative recovery. Dexmedetomidine, a selective alpha-2 adrenergic agonist, provides sedation and analgesia without significant respiratory depression. Esketamine, the S-enantiomer of ketamine, acts as a potent NMDA receptor antagonist to prevent central sensitization and hyperalgesia. Lidocaine, a voltage-gated sodium channel blocker, contributes systemic anti-inflammatory and analgesic properties when administered intravenously. The primary goal of this triple-drug combination is to reduce postoperative pain and opioid consumption, thereby accelerating recovery and minimizing opioid-related complications in the bariatric surgical population.
- Other names
- dexmedetomidine + esketamine + lidocaine cocktail
02
Targets
HCN (HCN channel family)NMDAR (Glutamate receptor ionotropic, NMDA)ADRA2A (α2A)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on dexmedetomidine + esketamine + lidocaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexmedetomidine + esketamine + lidocaine.